Julie E Lang1, Alexander Ring2, Tania Porras3, Pushpinder Kaur3, Victoria A Forte4, Neal Mineyev3, Debu Tripathy5, Michael F Press6, Daniel Campo7. 1. Section of Surgical Oncology, Department of Surgery and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA. julie.lang@med.usc.edu. 2. Department of Oncology, University Hospital Zurich, Zurich, Switzerland. 3. Section of Surgical Oncology, Department of Surgery and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA. 4. Division of Medical Oncology, Department of Medicine, Maimonides Medical Center, New York, NY, USA. 5. Department of Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Pathology and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA. 7. Department of Biological Sciences, University of Southern California, Los Angeles, CA, USA.
Abstract
BACKGROUND: We characterized the whole transcriptome of circulating tumor cells (CTCs) in stage II-III breast cancer to evaluate correlations with primary tumor biology. METHODS: CTCs were isolated from peripheral blood (PB) via immunomagnetic enrichment followed by fluorescence-activated cell sorting (IE/FACS). CTCs, PB, and fresh tumors were profiled using RNA-seq. Formalin-fixed, paraffin-embedded (FFPE) tumors were subjected to RNA-seq and NanoString PAM50 assays with risk of recurrence (ROR) scores. RESULTS: CTCs were detected in 29/33 (88%) patients. We selected 21 cases to attempt RNA-seq (median number of CTCs = 9). Sixteen CTC samples yielded results that passed quality-control metrics, and these samples had a median of 4,311,255 uniquely mapped reads (less than PB or tumors). Intrinsic subtype predicted by comparing estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) versus PAM50 for FFPE tumors was 85% concordant. However, CTC RNA-seq subtype assessed by the PAM50 classification genes was highly discordant, both with the subtype predicted by ER/PR/HER2 and by PAM50 tumors. Two patients died of metastatic disease, both of whom had high ROR scores and high CTC counts. We identified significant genes, canonical pathways, upstream regulators, and molecular interaction networks comparing CTCs by various clinical factors. We also identified a 75-gene signature with highest expression in CTCs and tumors taken together that was prognostic in The Cancer Genome Atlas and Molecular Taxonomy of Breast Cancer International Consortium datasets. CONCLUSION: It is feasible to use RNA-seq of CTCs in non-metastatic patients to discover novel tumor biology characteristics.
BACKGROUND: We characterized the whole transcriptome of circulating tumor cells (CTCs) in stage II-III breast cancer to evaluate correlations with primary tumor biology. METHODS: CTCs were isolated from peripheral blood (PB) via immunomagnetic enrichment followed by fluorescence-activated cell sorting (IE/FACS). CTCs, PB, and fresh tumors were profiled using RNA-seq. Formalin-fixed, paraffin-embedded (FFPE) tumors were subjected to RNA-seq and NanoString PAM50 assays with risk of recurrence (ROR) scores. RESULTS: CTCs were detected in 29/33 (88%) patients. We selected 21 cases to attempt RNA-seq (median number of CTCs = 9). Sixteen CTC samples yielded results that passed quality-control metrics, and these samples had a median of 4,311,255 uniquely mapped reads (less than PB or tumors). Intrinsic subtype predicted by comparing estrogen receptor (ER), progesterone receptor (PR), and humanepidermal growth factor receptor 2 (HER2) versus PAM50 for FFPE tumors was 85% concordant. However, CTC RNA-seq subtype assessed by the PAM50 classification genes was highly discordant, both with the subtype predicted by ER/PR/HER2 and by PAM50 tumors. Two patients died of metastatic disease, both of whom had high ROR scores and high CTC counts. We identified significant genes, canonical pathways, upstream regulators, and molecular interaction networks comparing CTCs by various clinical factors. We also identified a 75-gene signature with highest expression in CTCs and tumors taken together that was prognostic in The Cancer Genome Atlas and Molecular Taxonomy of Breast Cancer International Consortium datasets. CONCLUSION: It is feasible to use RNA-seq of CTCs in non-metastatic patients to discover novel tumor biology characteristics.
Authors: G Thomas Budd; Massimo Cristofanilli; Mathew J Ellis; Allison Stopeck; Ernest Borden; M Craig Miller; Jeri Matera; Madeline Repollet; Gerald V Doyle; Leon W M M Terstappen; Daniel F Hayes Journal: Clin Cancer Res Date: 2006-11-01 Impact factor: 12.531
Authors: Julie E Lang; Janet H Scott; Denise M Wolf; Petr Novak; Vasu Punj; Mark Jesus M Magbanua; Weizhu Zhu; Neal Mineyev; Christopher M Haqq; Julia R Crothers; Laura J Esserman; Debasish Tripathy; Laura van 't Veer; John W Park Journal: Breast Cancer Res Treat Date: 2014-11-29 Impact factor: 4.872
Authors: Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark Journal: J Natl Cancer Inst Date: 2005-08-17 Impact factor: 13.506
Authors: Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes Journal: N Engl J Med Date: 2004-08-19 Impact factor: 91.245
Authors: Deena M A Gendoo; Natchar Ratanasirigulchai; Markus S Schröder; Laia Paré; Joel S Parker; Aleix Prat; Benjamin Haibe-Kains Journal: Bioinformatics Date: 2015-11-24 Impact factor: 6.937
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Julie E Lang; Mark Jesus M Magbanua; Janet H Scott; G Mike Makrigiorgos; Gang Wang; Scot Federman; Laura J Esserman; John W Park; Christopher M Haqq Journal: BMC Genomics Date: 2009-07-20 Impact factor: 3.969
Authors: Ashley A Powell; Amirali H Talasaz; Haiyu Zhang; Marc A Coram; Anupama Reddy; Glenn Deng; Melinda L Telli; Ranjana H Advani; Robert W Carlson; Joseph A Mollick; Shruti Sheth; Allison W Kurian; James M Ford; Frank E Stockdale; Stephen R Quake; R Fabian Pease; Michael N Mindrinos; Gyan Bhanot; Shanaz H Dairkee; Ronald W Davis; Stefanie S Jeffrey Journal: PLoS One Date: 2012-05-07 Impact factor: 3.240
Authors: Mark Jesus M Magbanua; Christina Yau; Denise M Wolf; Jin Sun Lee; Aheli Chattopadhyay; Janet H Scott; Erin Bowlby-Yoder; E Shelley Hwang; Michael Alvarado; Cheryl A Ewing; Amy L Delson; Laura J Van't Veer; Laura Esserman; John W Park Journal: Clin Cancer Res Date: 2019-05-29 Impact factor: 12.531
Authors: Paulina Krzyszczyk; Alison Acevedo; Erika J Davidoff; Lauren M Timmins; Ileana Marrero-Berrios; Misaal Patel; Corina White; Christopher Lowe; Joseph J Sherba; Clara Hartmanshenn; Kate M O'Neill; Max L Balter; Zachary R Fritz; Ioannis P Androulakis; Rene S Schloss; Martin L Yarmush Journal: Technology (Singap World Sci) Date: 2019-01-11
Authors: Vishnu C Ramani; Clementine A Lemaire; Melanie Triboulet; Kerriann M Casey; Kyra Heirich; Corinne Renier; José G Vilches-Moure; Rakhi Gupta; Aryana M Razmara; Haiyu Zhang; George W Sledge; Elodie Sollier; Stefanie S Jeffrey Journal: Breast Cancer Res Date: 2019-08-28 Impact factor: 6.466
Authors: Tobias Mederer; Kai J Wessel; Bernardo Tavora; Simon Ruffing; Mahan Sadjadi; Marc Missmahl; Benjamin N Ostendorf; Xuhang Liu; Ji-Young Kim; Olav Olsen; Alana L Welm; Hani Goodarzi; Sohail F Tavazoie Journal: Nature Date: 2020-09-30 Impact factor: 69.504